<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27139" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Phosphodiesterase Inhibitors</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Padda</surname>
            <given-names>Inderbir S.</given-names>
          </name>
          <aff>Richmond University Medical Center/Mount Sinai</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tripp</surname>
            <given-names>Jayson</given-names>
          </name>
          <aff>CUSOM/Cape Fear Valley Health Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Inderbir Padda declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jayson Tripp declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27139.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Phosphodiesterase inhibitors are class medications used in the management and treatment of chronic obstructive pulmonary disease(COPD), erectile dysfunction(ED), pulmonary arterial hypertension(PAH), benign prostatic hyperplasia(BPH), acute decompensated heart failure, psoriasis, psoriatic arthritis(PA), atopic dermatitis(AD), and neonatal apnea. In the class of medications that prevent cAMP and/or cGMP degradation, it exhibits smooth muscle relaxation, vasodilatory, and bronchodilatory effects. This activity outline and describes the indications, action, and contraindications for phosphodiesterase inhibitors as a valuable agent in the management of chronic obstructive pulmonary disease(COPD), erectile dysfunction(ED), pulmonary arterial hypertension(PAH), acute decompensated heart failure, psoriasis, psoriatic arthritis(PA), and other disorders when applicable. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, monitoring, relevant interactions) pertinent for members of the interprofessional team in the management and care of patients with chronic obstructive pulmonary disease(COPD), erectile dysfunction(ED), pulmonary arterial hypertension(PAH), and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the mechanism of action of various phosphodiesterase inhibitors.</p></list-item><list-item><p>Identify the different classes of phosphodiesterase inhibitors.</p></list-item><list-item><p>Outline the proper monitoring for the various classes of phosphodiesterase inhibitors.</p></list-item><list-item><p>Summarize the interprofessional team approach for enhancing care coordination and communication to improve phosphodiesterase inhibitors therapy and optimize outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27139&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27139">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27139.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Phosphodiesterase inhibitors (PDE inhibitors) are a class of agents acting on specific phosphodiesterase enzymes in target cells and are FDA approved for the management of chronic obstructive pulmonary disease, erectile dysfunction, pulmonary arterial hypertension, psoriasis, psoriatic arthritis, and atopic dermatitis.<xref ref-type="bibr" rid="article-27139.r1">[1]</xref><xref ref-type="bibr" rid="article-27139.r2">[2]</xref>&#x000a0;Phosphodiesterase enzymes' essential role serves to separate the phosphate group from the target cell and decrease cyclic adenosine monophosphate (cAMP) or cyclic guanosine monophosphate (cGMP). The inhibition of these enzymes further prevents the degradation of cAMP or cGMP, exhibiting smooth muscle relaxation, vasodilatory, and bronchodilatory effects.<xref ref-type="bibr" rid="article-27139.r1">[1]</xref>&#x000a0;</p>
        <p>Among the phosphodiesterase inhibitors, sildenafil is the more common agent acting on&#x000a0;PDE-5 and is FDA-approved in 1998 for erectile dysfunction.<xref ref-type="bibr" rid="article-27139.r3">[3]</xref>&#x000a0;Sildenafil use is not limited to the treatment of erectile dysfunction(ED) and obtained FDA approval in 2005 to treat pulmonary arterial hypertension (PAH) in adults.<xref ref-type="bibr" rid="article-27139.r4">[4]</xref> The use of sildenafil in pediatric populations for pulmonary arterial hypertension(PAH)&#x000a0;has not received approval and is&#x000a0;considered off-label use.<xref ref-type="bibr" rid="article-27139.r5">[5]</xref>&#x000a0;Vardenafil and avanafil are other PDE-5 inhibitors, also approved for erectile dysfunction(ED).&#x000a0;Tadalafil is a PDE-5 inhibitor approved to treat benign prostatic hyperplasia(BPH) and erectile dysfunction(ED). As both conditions may coincide in the&#x000a0;later durations of life,&#x000a0;tadalafil may be used as monotherapy for its therapeutic use to treat both conditions.<xref ref-type="bibr" rid="article-27139.r6">[6]</xref></p>
        <p>Cilostazol is a PDE-3 inhibitor that reversibly inhibits platelets from aggregation and is&#x000a0;indicated to treat intermittent claudication from peripheral arterial disease(PAD). Dipyridamole is also a PDE-3 inhibitor and is used for postoperative prophylaxis for thrombosis, but its action on the PDE-3 enzyme is relatively weak.&#x000a0;Dipyridamole can also be a diagnostic tool as a pharmacologic nuclear stress test. Dypriadamole increases perfusion to the myocardium, revealing reversible and irreversible ischemic areas in the myocardial muscle.<xref ref-type="bibr" rid="article-27139.r7">[7]</xref>&#x000a0;</p>
        <p>Milrinone and amrinone also inhibit PDE-3 enzymes, but their actions target heart cells, increasing cAMP in the myocardium, and producing&#x000a0;a positive inotropic effect.&#x000a0;Both agents&#x000a0;may be used short-term for decompensated heart failure as&#x000a0;therapy for&#x000a0;greater durations may precipitate ventricular arrhythmias. Roflumilast is a PDE-4 inhibitor that acts on the target cells of lung tissue and is indicated for the treatment of reducing COPD exacerbations. Other PDE-4 inhibitors include&#x000a0;apremilast and crisaborole; their uses are nonpulmonary, and indications include treating psoriasis, psoriatic arthritis(PA), and atopic dermatitis(AD), respectively, due to their action of decreasing pro-inflammatory chemokines. PDE-4 inhibitors decrease pro-inflammatory mediators and cause bronchodilation by inhibiting the degradation of cAMP. Theophylline is a non-specific&#x000a0;PDE inhibitor with weak&#x000a0;action on phosphodiesterase enzymes and has approval for symptomatic relief of chronic obstructive pulmonary disease(COPD).<xref ref-type="bibr" rid="article-27139.r8">[8]</xref>&#x000a0;</p>
        <p>Pentoxifylline is a xanthine analog and is a non-selective phosphodiesterase inhibitor, FDA approved in 1984 for muscle pain caused by intermittent claudication in chronic peripheral arterial disease. Anagrelide is a PDE-3 inhibitor approved for the treatment of thrombocythemia caused by myeloproliferative disorders.&#x000a0;Ibudilast is a non-selective PDE inhibitor that has not secured approval by the FDA for its use. Ibudilast action causes dilations of the bronchioles and&#x000a0;has been used to treat asthma in Japan since 1989.<xref ref-type="bibr" rid="article-27139.r9">[9]</xref><xref ref-type="bibr" rid="article-27139.r10">[10]</xref>&#x000a0;The agent is also said to cross the blood-brain barrier, exert anti-inflammatory actions in the central nervous system, and may be a hopeful agent for inflammatory neurological disorders.<xref ref-type="bibr" rid="article-27139.r9">[9]</xref><xref ref-type="bibr" rid="article-27139.r10">[10]</xref>&#x000a0;Caffeine, one of the most popularly utilized psychoactive compounds used globally, also inhibits phosphodiesterase as one of its three mechanisms of action. It is labeled and generally recognized as safe (GRAS) by the FDA since 1958.<xref ref-type="bibr" rid="article-27139.r11">[11]</xref><xref ref-type="bibr" rid="article-27139.r12">[12]</xref>&#x000a0;Caffeine is a CNS&#x000a0;stimulant used for fatigue, drowsiness, enhancing memory, cognition, and performance.<xref ref-type="bibr" rid="article-27139.r12">[12]</xref><xref ref-type="bibr" rid="article-27139.r11">[11]</xref> Caffeine citrate has been used to treat apnea of prematurity in neonates gestation age of twenty-two weeks to less than thirty-three weeks and received approval in 1999 for its use.</p>
        <p>
<bold>Types</bold>
<xref ref-type="bibr" rid="article-27139.r13">[13]</xref>
<xref ref-type="bibr" rid="article-27139.r14">[14]</xref>
<xref ref-type="bibr" rid="article-27139.r15">[15]</xref>
<xref ref-type="bibr" rid="article-27139.r1">[1]</xref>
<xref ref-type="bibr" rid="article-27139.r2">[2]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>PDE-3 inhibitors: cilostazol, dipyridamole, milrinone, and amrinone</p>
          </list-item>
          <list-item>
            <p>PDE-4 inhibitors: roflumilast, apremilast, crisaborole</p>
          </list-item>
          <list-item>
            <p>PDE-5 inhibitors: sildenafil, tadalafil, vardenafil, and avanafil</p>
          </list-item>
          <list-item>
            <p>Non-specific PDE inhibitors: theophylline, ibudilast</p>
          </list-item>
        </list>
        <p>
<bold>FDA-approved Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Erectile dysfunction(ED): sildenafil, tadalafil, vardenafil, and avanafil</p>
          </list-item>
          <list-item>
            <p>Benign prostatic hyperplasia (BPH):&#x000a0;tadalafil</p>
          </list-item>
          <list-item>
            <p>Pulmonary arterial hypertension(PAH):&#x000a0; sildenafil,&#x000a0;tadalafil</p>
          </list-item>
          <list-item>
            <p>Psoriatic arthritis(PA): apremilast</p>
          </list-item>
          <list-item>
            <p>Psoriasis: apremilast</p>
          </list-item>
          <list-item>
            <p>Chronic obstructive pulmonary disease(COPD):&#x000a0;roflumilast, theophylline</p>
          </list-item>
          <list-item>
            <p>Peripheral arterial disease (PAD): cilostazol, pentoxifylline</p>
          </list-item>
          <list-item>
            <p>Postoperative thromboembolic prophylaxis: dipyridamole</p>
          </list-item>
          <list-item>
            <p>Decompensated cardiac failure: milrinone, amrinone</p>
          </list-item>
          <list-item>
            <p>Atopic dermatitis(AD):crisaborole</p>
          </list-item>
          <list-item>
            <p>Thrombocythemia: anagrelide</p>
          </list-item>
          <list-item>
            <p>Neonatal apnea: caffeine citrate</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27139.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Cyclic adenosine monophosphate(cAMP) and cyclic guanosine monophosphate (cGMP) are intracellular second messenger molecules degraded and inactivated by the enzyme phosphodiesterases(PDE).<xref ref-type="bibr" rid="article-27139.r16">[16]</xref><xref ref-type="bibr" rid="article-27139.r17">[17]</xref><xref ref-type="bibr" rid="article-27139.r18">[18]</xref> Phosphodiesterase inhibitors exert their effects on their targeted phosphodiesterase enzymes(PDE-3, PDE-4, PDE-5), preventing cGMP or cAMP degradation, further increasing&#x000a0;their levels in smooth muscle cells, causing relaxation and vasodilatory effect in target cells. PDE-3&#x000a0;inhibitors&#x000a0;exert&#x000a0;their effects by increasing cAMP levels in the myocardium, peripheral vasculature, and platelets. This further causes positive inotropic effects by increasing ionized calcium in the myocardium, vasodilation of the peripheral vessels, and preventing platelet aggregation and can be used to treat decompensated cardiac failure and peripheral arterial disease(PAD).</p>
        <p>PDE-4 is an enzyme found in cells of the lungs, and PDE-4 inhibitors inhibit the degradation of intracellular cyclic adenosine monophosphate(cAMP) and increase cAMP levels in target cells,&#x000a0;further causing bronchial muscle relaxation. Along with its effects on the lungs, it also decreases pro-inflammatory mediators.<xref ref-type="bibr" rid="article-27139.r1">[1]</xref>&#x000a0;These&#x000a0;agents are useful in treating COPD, psoriatic arthritis(PA), and atopic dermatitis(AD).&#x000a0;Crisaborole is a PDE-4 inhibitor indicated for mild to moderate atopic dermatitis, and its mechanism of action its therapeutic&#x000a0;effect is not fully understood.</p>
        <p>PDE-5 inhibitors&#x000a0;carry out their action by preventing the breakdown of cyclic guanosine monophosphate (cGMP), further increasing cGMP levels in target cells. The endothelial cells of the penile smooth muscle corpus cavernosum release nitric oxide(NO), which initiates the enzyme guanylate cyclase, further&#x000a0;enhancing&#x000a0;the&#x000a0;synthesis of cyclic guanosine monophosphate (cGMP). The prevention of&#x000a0;cGMP breakdown further prolongs an erection and is used therapeutically to treat erectile dysfunction(ED).<xref ref-type="bibr" rid="article-27139.r14">[14]</xref>&#x000a0;PDE-5 inhibitors also cause pulmonary vasodilation and may be useful for treating pulmonary arterial hypertension(PAH) as&#x000a0;PAH may be correlated with the weakened release of nitric oxide in the pulmonary vasculature, resulting in decreased cGMP levels. Nonspecific inhibitors(PDE-3,4,5) exert their action, increasing cAMP levels in the pulmonary vasculature, resulting in bronchial relaxation and further decreasing pro-inflammatory mediators.<xref ref-type="bibr" rid="article-27139.r19">[19]</xref>&#x000a0;</p>
        <p>Theophylline is a nonspecific phosphodiesterase inhibitor used to treat COPD, and the mechanism of action is not&#x000a0;entirely understood.<xref ref-type="bibr" rid="article-27139.r19">[19]</xref>&#x000a0;Although not fully understood, pentoxifylline's mechanism of action is believed to act by the nonselective inhibition of phosphodiesterase enzymes similar to theophylline. This action further enhances blood flow and perfusion in the limbs by increasing erythrocyte flexibility, decreasing blood viscosity, decreasing cell proliferation, and reduced inflammation. This mechanism allows pentoxifylline to be used therapeutically in patients suffering from muscle aches and pain associated with peripheral arterial disease.<xref ref-type="bibr" rid="article-27139.r20">[20]</xref><xref ref-type="bibr" rid="article-27139.r21">[21]</xref></p>
        <p>Anagrelide exerts its effects by inhibiting PDE-3, decreasing the platelet count and platelet aggregation. The full agent's action is still being studied and is said to interrupt the cell cycle post miosis of megakaryocyte development, decreasing&#x000a0;megakaryocyte's size and ploidy. This drug helps decrease platelet count,&#x000a0;further preventing thrombotic complications in myeloproliferative disorders such as essential thrombocytopenia, polycythemia vera, and chronic myeloid leukemia.<xref ref-type="bibr" rid="article-27139.r20">[20]</xref>&#x000a0;Ibudilast exerts its actions by nonselective phosphodiesterase inhibition of PDE-3, PDE-4, PDE-10, and PDE-11, decreasing nitric oxide production, pro-inflammatory chemokines,&#x000a0;LTB4, and toll-like receptor 4 (TLR4).<xref ref-type="bibr" rid="article-27139.r16">[16]</xref>&#x000a0;</p>
        <p>Ibudilast's bronchodilator and anti-inflammatory effects have been used therapeutically in Japan to treat bronchial asthma and post-stroke complications. Caffeine exerts its effects on phosphodiesterase enzymes by nonselective inhibition of PDE1, PDE4, and PDE5, promoting cAMP accumulation. Caffeine also inhibits adenosine and&#x000a0;gamma-aminobutyric acid (GABA) receptors and enhances intracellular calcium release, improving and enhancing cognition, memory,&#x000a0;energy, sleep, fatigue, and drowsiness.<xref ref-type="bibr" rid="article-27139.r22">[22]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-27139.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Phosphodiesterase inhibitors (PDE inhibitors) are available&#x000a0;in&#x000a0;oral tablets, injection form, and topical ointment.</p>
        <p>
<bold>Erectile Dysfunction</bold>
<xref ref-type="bibr" rid="article-27139.r13">[13]</xref>
<xref ref-type="bibr" rid="article-27139.r14">[14]</xref>
<xref ref-type="bibr" rid="article-27139.r23">[23]</xref>
<xref ref-type="bibr" rid="article-27139.r24">[24]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Sildenafil 25 to 100 mg/day (available in 25 mg, 50 mg, and 100 mg tablets)</p>
          </list-item>
          <list-item>
            <p>Vardenafil 5 to 20 mg/day (available in 2.5 mg, 5 mg, 10 mg, 20 mg&#x000a0;tablets)</p>
          </list-item>
          <list-item>
            <p>Tadalafil 5 to 20 mg/day (available in 2.5 mg, 5 mg, 10 mg, and 20 mg&#x000a0;tablets)</p>
          </list-item>
          <list-item>
            <p>Avanafil 50 mg to 200 mg/day (available in 50 mg, 100 mg, and 200 mg tablets)</p>
          </list-item>
        </list>
        <p>These agents can be&#x000a0;administered 30 to 60 minutes&#x000a0;prior to sexual intercourse.&#x000a0;</p>
        <p>
<bold>Benign Prostatic Hyperplasia (BPH)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Tadalafil 5 mg/day</p>
          </list-item>
        </list>
        <p>Tadalafil is available in 2.5 mg, 5 mg, 10 mg, and 20 mg tablets.</p>
        <p>
<bold>Pulmonary Arterial Hypertension (PAH)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Sildenafil 20 mg three times per day</p>
          </list-item>
          <list-item>
            <p>Tadalafil 40 mg/day</p>
          </list-item>
        </list>
        <p>Sildenafil is available in 20 mg and 10 mg (12.5ml) vials and can be administered orally or via intravenous injection for pulmonary arterial hypertension.</p>
        <p>
<bold>Psoriatic Arthritis (PA)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Apremilast</p>
          </list-item>
        </list>
        <p>Day 1: 10 mg/day&#x000a0;&#x000a0;</p>
        <p>Day 2: 10 mg twice a day</p>
        <p>Day 3: 10 mg (morning) and 20 mg (evening)</p>
        <p>Day 4: 20 mg (morning) and 20 mg (evening)</p>
        <p>Day 5: 20 mg (morning) and 30 mg (evening)</p>
        <p>Day 6: 30 mg twice daily</p>
        <p>Apremilast tablets are available in 10 mg, 20 mg, and 30 mg tablets and are administered orally.</p>
        <p>
<bold>Chronic Obstructive Pulmonary Disease (COPD)</bold>
<xref ref-type="bibr" rid="article-27139.r15">[15]</xref>
<bold>&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Theophylline&#x000a0;10&#x000a0;to 15 mcg/mL serum concentration for acute exacerbation.</p>
          </list-item>
          <list-item>
            <p>Roflumilast&#x000a0;500 mcg/day</p>
          </list-item>
        </list>
        <p>Theophylline is available in 200 mg, 400 mg, and 800 mg in 5% dextrose for IV injection.Roflumilast&#x000a0;is available in 500mg tablets for oral administration.</p>
        <p>
<bold>Peripheral Arterial Disease (PAD)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Cilostazol&#x000a0;100 mg&#x000a0;two times&#x000a0;a day&#x000a0;(available in 50 mg and 100 mg tablets and are administered orally)</p>
          </list-item>
          <list-item>
            <p>Pentoxifylline 400 mg three times a day&#x000a0; (available in 400 mg extended-release tablets and are administered orally)</p>
          </list-item>
        </list>
        <p>
<bold>Postoperative Thromboembolic Prophylaxis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dipyridamole&#x000a0;75 mg to 100 mg four times&#x000a0;a day (available in&#x000a0;25 mg, 50 mg, and 75 mg tablets&#x000a0;and are administered orally)</p>
          </list-item>
        </list>
        <p>
<bold>Decompensated Cardiac Failure</bold>
<xref ref-type="bibr" rid="article-27139.r25">[25]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Milrinone&#x000a0;100 ng/mL to 300 ng/mL (available in&#x000a0;10 ml, 20 ml, and 50 ml vials for injection)</p>
          </list-item>
          <list-item>
            <p>Amrinone&#x000a0;0.5 to 7.0 mcg/mL (available in 5 mg/mL&#x000a0;for injection)</p>
          </list-item>
        </list>
        <p>
<bold>Atopic Dermatitis (AD)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Crisaborole (available as 2% topical ointment)</p>
          </list-item>
        </list>
        <p>Crisaborole can be used in patients ages two years or older for topical use only. It should be applied to the affected areas two times daily.</p>
        <p>
<bold>Thrombocythemia</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Anagrelide 0.5 mg 4 times a day or 1mg twice a day. (available in 0.5 mg tablets and are administered orally)</p>
          </list-item>
        </list>
        <p>
<bold>Neonatal Apnea</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Caffeine Citrate 10 mg/ml to 20 mg/ml&#x000a0;&#x000a0;(available as a solution for oral and injectable administration)</p>
          </list-item>
        </list>
        <p>
<bold>Fatigue and Drowsiness</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Caffeine 100 mg to 200 mg (available as tablets or capsules for oral administration). It should not be consumed six hours before bedtime.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27139.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Cilostazol</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal symptoms: nausea, diarrhea, abnormal stools</p>
          </list-item>
          <list-item>
            <p>Tachycardia</p>
          </list-item>
          <list-item>
            <p>Palpitations</p>
          </list-item>
        </list>
        <p>
<bold>Dipyridamole</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dizziness</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal distress</p>
          </list-item>
          <list-item>
            <p>Rash</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Elevated liver enzyme</p>
          </list-item>
        </list>
        <p>
<bold>Milrinone</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Ventricular arrhythmias</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Hypokalemia</p>
          </list-item>
          <list-item>
            <p>Tremor</p>
          </list-item>
        </list>
        <p>
<bold>Amrinone</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Thrombocytopenia</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal symptoms: nausea, vomiting, abdominal pain</p>
          </list-item>
          <list-item>
            <p>Arrhythmia</p>
          </list-item>
          <list-item>
            <p>Hepatotoxicity</p>
          </list-item>
          <list-item>
            <p>Hypersensitivity</p>
          </list-item>
        </list>
        <p>
<bold>Roflumilast</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Gastrointestinal symptoms: nausea, vomiting, diarrhea</p>
          </list-item>
          <list-item>
            <p>Weight loss</p>
          </list-item>
          <list-item>
            <p>Decreased appetite</p>
          </list-item>
          <list-item>
            <p>Headache&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Insomnia</p>
          </list-item>
          <list-item>
            <p>Dizziness</p>
          </list-item>
          <list-item>
            <p>Anxiety</p>
          </list-item>
          <list-item>
            <p>Worsening depression</p>
          </list-item>
        </list>
        <p>
<bold>Apremilast</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Gastrointestinal symptoms: nausea, vomiting, diarrhea</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Worsening depression</p>
          </list-item>
          <list-item>
            <p>Suicidal thoughts</p>
          </list-item>
          <list-item>
            <p>Weight loss</p>
          </list-item>
          <list-item>
            <p>Upper respiratory infections</p>
          </list-item>
        </list>
        <p>
<bold>Crisaborole</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Burning on the site of application</p>
          </list-item>
          <list-item>
            <p>Hypersensitivity: pruritis, swelling, erythema</p>
          </list-item>
        </list>
        <p>
<bold>Sildenafil</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Flushing</p>
          </list-item>
          <list-item>
            <p>Visual disturbance</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal symptoms: dyspepsia, nausea</p>
          </list-item>
          <list-item>
            <p>Nasal congestion</p>
          </list-item>
          <list-item>
            <p>Priapism</p>
          </list-item>
          <list-item>
            <p>Hearing loss</p>
          </list-item>
          <list-item>
            <p>Back pain</p>
          </list-item>
          <list-item>
            <p>Decreased in blood pressure</p>
          </list-item>
          <list-item>
            <p>Rash</p>
          </list-item>
          <list-item>
            <p>Dizziness</p>
          </list-item>
          <list-item>
            <p>Hepatotoxicity</p>
          </list-item>
        </list>
        <p>
<bold>Tadalafil</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Headache (most common)</p>
          </list-item>
          <list-item>
            <p>Decreased in blood pressure</p>
          </list-item>
          <list-item>
            <p>Nasopharyngitis</p>
          </list-item>
          <list-item>
            <p>Myalgia</p>
          </list-item>
          <list-item>
            <p>Back pain</p>
          </list-item>
          <list-item>
            <p>Priapism</p>
          </list-item>
          <list-item>
            <p>Hearing loss</p>
          </list-item>
          <list-item>
            <p>Visual disturbance</p>
          </list-item>
        </list>
        <p>
<bold>Vardenafil</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Flushing</p>
          </list-item>
          <list-item>
            <p>Flu-like symptoms</p>
          </list-item>
          <list-item>
            <p>Sinusitis</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal symptoms: dyspepsia, nausea</p>
          </list-item>
          <list-item>
            <p>Priapism</p>
          </list-item>
          <list-item>
            <p>Hearing loss</p>
          </list-item>
          <list-item>
            <p>Increased creatinine kinase levels</p>
          </list-item>
          <list-item>
            <p>QT prolongation</p>
          </list-item>
        </list>
        <p>
<bold>Avanafil</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Flushing</p>
          </list-item>
          <list-item>
            <p>Back pain</p>
          </list-item>
          <list-item>
            <p>Nasal congestion</p>
          </list-item>
        </list>
        <p>
<bold>Theophylline</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypotension</p>
          </list-item>
          <list-item>
            <p>Tachycardia</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal symptoms: nausea, vomiting</p>
          </list-item>
          <list-item>
            <p>Seizures</p>
          </list-item>
          <list-item>
            <p>Arrhythmias</p>
          </list-item>
        </list>
        <p>
<bold>Pentoxifylline</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Gastrointestinal symptoms: dyspepsia, nausea, vomiting</p>
          </list-item>
          <list-item>
            <p>Dizziness</p>
          </list-item>
          <list-item>
            <p>Chest pain</p>
          </list-item>
          <list-item>
            <p>Arrhythmia</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
        </list>
        <p>
<bold>Anagrelide</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Palpitations</p>
          </list-item>
          <list-item>
            <p>Decreased blood pressure</p>
          </list-item>
          <list-item>
            <p>Diahrrea</p>
          </list-item>
          <list-item>
            <p>Asthenia</p>
          </list-item>
          <list-item>
            <p>Edema</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal symptoms: dyspepsia, nausea, vomiting</p>
          </list-item>
        </list>
        <p>
<bold>Ibudilast</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hyperhidrosis</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal symptoms: nausea, vomiting, diarrhea</p>
          </list-item>
        </list>
        <p>
<bold>Caffeine</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Tachycardia</p>
          </list-item>
          <list-item>
            <p>Palpitations</p>
          </list-item>
          <list-item>
            <p>Irritability</p>
          </list-item>
          <list-item>
            <p>Restlessness</p>
          </list-item>
          <list-item>
            <p>Decreased sleep</p>
          </list-item>
          <list-item>
            <p>Tremor</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal symptoms: nausea, vomiting, diarrhea</p>
          </list-item>
        </list>
        <p>Sildenafil, vardenafil, and tadalafil have been&#x000a0;associated&#x000a0;with hearing loss.<xref ref-type="bibr" rid="article-27139.r26">[26]</xref>&#x000a0;Often the hearing loss is unilateral and may&#x000a0;occur during the initial 24 hours after&#x000a0;administration of&#x000a0;the agent and is temporary in almost one-third of patients.<xref ref-type="bibr" rid="article-27139.r27">[27]</xref>&#x000a0;Patients should seek immediate medical&#x000a0;attention&#x000a0;if hearing loss does pursue. Although sildenafil is a PDE-5 inhibitor, it mildly has an inhibitory effect on a phosphodiesterase-6 enzyme found in the retinal rod and cone receptors. This may result in a "blue-tinted" visual disturbance in some subjects taking higher doses.<xref ref-type="bibr" rid="article-27139.r28">[28]</xref>&#x000a0;Patients also may experience increased sensitivity to the brightness of lights.</p>
        <p>These visual disruptions due to the electrical responses to light are temporary and reversible.<xref ref-type="bibr" rid="article-27139.r29">[29]</xref> Priapism is a reported adverse effect of phosphodiesterase-5 inhibitors. Patients who have erections lasting more than four hours should seek medical attention as permanent damage may result. Apremilast has an increased risk of depression. Patients&#x000a0;who have an underlying history of depression should be evaluated thoroughly prior to the initiation of apremilast.&#x000a0;Roflumilast may also worsen underlying depression or increased suicidal thoughts; a thorough&#x000a0;assessment should be conducted before therapy.</p>
      </sec>
      <sec id="article-27139.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Hypersensitivity is an absolute contraindication to all&#x000a0;phosphodiesterase inhibitors. Nitrites are contraindicated to use alongside PDE-5 inhibitors: sildenafil, tadalafil, vardenafil, and avanafil, as they may&#x000a0;result in severe hypotension.<xref ref-type="bibr" rid="article-27139.r30">[30]</xref> Relative contraindication such as pre-existing cardiovascular disease, resting hypotension, and anti-hypertensive use require evaluation before&#x000a0;phosphodiesterase inhibitor use.</p>
        <p>Heart failure of any sort is a contraindication to&#x000a0;cilostazol use. Patients taking medications that may cause QT prolongation or have congenital QT syndrome should avoid taking&#x000a0;vardenafil. Patients with hemostatic or bleeding disorders are contraindicated to&#x000a0;cilostazol use as its mechanism of action inhibits platelet aggregations and&#x000a0;may worsen the underlying conditions. Milrinone and amrinone are contraindicated in patients with pre-existing valvular disease of the aortic or pulmonic valve as they may cause outflow obstruction. Pentoxifylline is contraindicated in patients with a recent history of cerebral hemorrhage or retinal hemorrhage.</p>
        <p>
<bold>Black Box Warning</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Cilostazol: Heart failure is an absolute contraindication to&#x000a0;cilostazol use.</p>
          </list-item>
          <list-item>
            <p>Milrinone: Should not be used for greater than 48 hours for heart failure as it may cause ventricular arrhythmias and result in sudden death.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27139.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Medications that cause vasodilatory effects, such as antihypertensives, alpha-blockers, and amlodipine, should be avoided with concomitant use with phosphodiesterase-5 inhibitors. If used in sequence, patients should have routine monitoring, and therapy should be started on the lowest possible dosage as it&#x000a0;may result in&#x000a0;profound&#x000a0;hypotension, lightheadedness, and dizziness. Patients with renal insufficiency and&#x000a0;hepatic impairment&#x000a0;can result in higher serum concentrations of medication; dose adjustment may be necessary. Fluid and electrolytes require monitoring routinely with&#x000a0;milrinone use as it may precipitate hypokalemia and induce arrhythmias. Precautions are necessary for patients with underlying ophthalmopathy taking sildenafil, vardenafil, tadalafil, and avanafil as unexpected vision loss may occur unilaterally or bilaterally, which may be an indication of non-arteritic anterior ischemic optic neuropathy (NAION).<xref ref-type="bibr" rid="article-27139.r31">[31]</xref>&#x000a0;&#x000a0;</p>
        <p>Phosphodiesterase-5 inhibitors are substantially and quickly metabolized by the CYP3A4 enzyme found in the liver.<xref ref-type="bibr" rid="article-27139.r3">[3]</xref> CYP3A4 inhibitors such as ritonavir, ketoconazole, verapamil, itraconazole erythromycin, and grapefruit juice can increase serum concentrations of PDE-inhibitors and require dosing adjustments. Patients taking&#x000a0;cilostazol to manage peripheral arterial disease(PAD) should&#x000a0;routinely monitor platelet, and WBC counts as thrombocytopenia or leukopenia can develop.&#x000a0;Dipyridamole may cause an elevation in liver enzymes and should be monitored routinely and used with precaution in patients with pre-existing liver insufficiency. Amirinone use may cause thrombocytopenia and is hepatotoxic; platelet count and liver enzymes should be monitored routinely. Thrombocytopenia from amrinone may be dose-dependent and is said to be non-immune mediated.<xref ref-type="bibr" rid="article-27139.r32">[32]</xref>&#x000a0;</p>
        <p>Patients receiving treatment milrinone should be monitored via EKG as it can precipitate ventricular arrhythmias. Electrolytes should also be monitored with milrinone use as it can decrease serum potassium. Patients being treated with roflumilast and&#x000a0;apremilast should be followed for alterations in mood, such as worsening depression or suicidal thoughts, as it may precipitate underlying or undiagnosed mood disorders.&#x000a0;Anagrelide serum concentration can increase eightfold in&#x000a0;hepatic impairment. Liver function tests should be conducted before therapy, and platelet count requires routine monitoring for patients taking this medication.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Pregnancy Category B: apremilast, tadalafil, vardenafil,&#x000a0;dipyridamole</p>
          </list-item>
          <list-item>
            <p>Pregnancy Category C: sildenafil, theophylline, roflumilast,&#x000a0;avanafil,&#x000a0;cilostazol, milrinone, anagrelide</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27139.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>PDE-4 inhibitor theophylline serum concentrations of more than 20 mcg/mL are in a toxic range.<xref ref-type="bibr" rid="article-27139.r33">[33]</xref>&#x000a0;Theophylline-induced seizures and arrhythmias prompt treatment immediately as it may result in mortality from hemodynamic compromise at serum concentrations of 30 mcg/mL or greater. Therapy with anticonvulsants such as benzodiazepine and antiarrhythmic treatment should start immediately. PDE-5 and PDE-3 inhibitors undergo hepatic metabolism, and inhibitors of CYP3A4 or CYP2C19 can increase the serum drug concentrations of therapy. Dose modifications are required before the initiation of treatment to avoid adverse effects.</p>
        <p>Although uncommon with sildenafil use, Hepatoxicity has been reported,&#x000a0;but studies&#x000a0;of the correlation are limited.<xref ref-type="bibr" rid="article-27139.r3">[3]</xref>&#x000a0;Anagrelide should not be administered in patients with pre-existing liver disease as it can result in large increases in drug concentration. Drug toxicity may ensue with a dosage of 10 mg per day or greater or 2.5 mg in a single dose of anagrelide.&#x000a0;Caffeine toxicities can pursue at 50 mg/L to 350 mg/L, causing arrhythmias, seizures, and mortality.<xref ref-type="bibr" rid="article-27139.r34">[34]</xref>&#x000a0;Caffeine toxicity-induced seizures can be treated with benzodiazepines, and dysrhythmias&#x000a0;have shown successful&#x000a0;recovery with the treatment&#x000a0;of beta-blockers such as metoprolol or esmolol.<xref ref-type="bibr" rid="article-27139.r35">[35]</xref><xref ref-type="bibr" rid="article-27139.r36">[36]</xref></p>
      </sec>
      <sec id="article-27139.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Phosphodiesterase inhibitors (PDE inhibitors) are a class of agents acting on phosphodiesterase enzymes. They are FDA approved to manage chronic obstructive pulmonary disease, erectile dysfunction, pulmonary arterial hypertension, acute decompensated heart failure, psoriasis, psoriatic arthritis, atopic dermatitis, and neonatal apnea. The management of patients administered PDE inhibitors requires decisive care and decision-making from an interprofessional team of healthcare professionals, as the management of each condition can lead to a better quality of life for patients. These healthcare professionals include a primary care provider, a specialist (cardiologist, pulmonologist, urologist, or rheumatologist), depending on the management of the disease, a nurse, and a pharmacist. The primary care provider and specialist should be familiar with PDE inhibitors, their indications and use, adverse effects, and contraindications. In addition, patients should be fully educated on the side effects of therapy, such as headaches and decreased blood pressure that may cause dizziness and lightheadedness.</p>
        <p>The patient should also be advised to seek medical attention immediately if more concerning effects such as visual disturbances, hearing loss, and priapism for long periods occur using PDE-5 inhibitors (sildenafil, tadalafil, vardenafil, and avanafil). The elderly population prescribed therapy for erectile dysfunction should be thoroughly evaluated in case dosing modifications may be needed for renal and hepatic impairment in this patient population. The clinician should be aware of any other medications the patient may be taking short-term or long-term. Phosphodiesterase inhibitors can cross-react with other agents as they are metabolized by the cytochrome p450 system in the liver resulting in subtherapeutic or toxic serum concentrations.</p>
        <p>Cardiac risk factors should be carefully assessed before treatment as this class of medications may cause a decrease in blood pressure and precipitate or further worsen an underlying cardiac disease. Patients taking antihypertensives should be advised about their concurrent use with phosphodiesterase inhibitors as it can cause symptomatic life-threatening hypotension. PDE-4 inhibitors may worsen or precipitate psychiatric symptoms such as suicidal thoughts and depression in susceptible individuals. The use of this medication class can be discussed with a psychiatrist before administration in select individuals.</p>
        <p>Nonselective phosphodiesterase inhibitors such as theophylline and caffeine should be used cautiously as toxicity can result in seizures, arrhythmias, and mortality. If seizures or arrhythmias occur, patients should be treated promptly with benzodiazepines and beta-blockers as indicated and as needed until the patient is stabilized. The primary care clinician should periodically monitor patients as some phosphodiesterase inhibitors may cause elevations in liver enzymes, thrombocytopenia, and electrolyte disturbances. Joint decision-making and interprofessional interaction are essential components to decrease adverse effects and enhance patient-centered care to achieve the desired outcome.</p>
      </sec>
      <sec id="article-27139.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27139&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27139">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27139/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27139">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27139.s11">
        <title>References</title>
        <ref id="article-27139.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zebda</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Paller</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Phosphodiesterase 4 inhibitors.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>78</volume>
            <issue>3 Suppl 1</issue>
            <fpage>S43</fpage>
            <page-range>S43-S52</page-range>
            <pub-id pub-id-type="pmid">29248522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giembycz</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease.</article-title>
            <source>Proc Am Thorac Soc</source>
            <year>2005</year>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>326</fpage>
            <page-range>326-33; discussion 340-1</page-range>
            <pub-id pub-id-type="pmid">16267357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graziano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Montana</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zaami</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rotolo</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Minutillo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Busard&#x000f2;</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Marinelli</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Sildenafil-associated hepatoxicity: a review of the literature.</article-title>
            <source>Eur Rev Med Pharmacol Sci</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>21</volume>
            <issue>1 Suppl</issue>
            <fpage>17</fpage>
            <page-range>17-22</page-range>
            <pub-id pub-id-type="pmid">28379598</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhogal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khraisha</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Al Madani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Treece</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baumrucker</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>TK</given-names>
              </name>
            </person-group>
            <article-title>Sildenafil for Pulmonary Arterial Hypertension.</article-title>
            <source>Am J Ther</source>
            <year>2019</year>
            <season>Jul/Aug</season>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>e520</fpage>
            <page-range>e520-e526</page-range>
            <pub-id pub-id-type="pmid">30946047</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dhariwal</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Bavdekar</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>Sildenafil in pediatric pulmonary arterial hypertension.</article-title>
            <source>J Postgrad Med</source>
            <year>2015</year>
            <season>Jul-Sep</season>
            <volume>61</volume>
            <issue>3</issue>
            <fpage>181</fpage>
            <page-range>181-92</page-range>
            <pub-id pub-id-type="pmid">26119438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000f3;nica</surname>
                <given-names>FZ</given-names>
              </name>
              <name>
                <surname>De Nucci</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Tadalafil for the treatment of benign prostatic hyperplasia.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>8</issue>
            <fpage>929</fpage>
            <page-range>929-937</page-range>
            <pub-id pub-id-type="pmid">30901259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r7">
          <label>7</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Samarany</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Dipyridamole Nuclear Stress Test</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">31335041</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hendeles</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Massanari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weinberger</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Update on the pharmacodynamics and pharmacokinetics of theophylline.</article-title>
            <source>Chest</source>
            <year>1985</year>
            <month>Aug</month>
            <volume>88</volume>
            <issue>2 Suppl</issue>
            <fpage>103S</fpage>
            <page-range>103S-111S</page-range>
            <pub-id pub-id-type="pmid">3893922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwenkgrub</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zaremba</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mirowska-Guzel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kurkowska-Jastrz&#x00119;bska</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Ibudilast: a non&#x02011;selective phosphodiesterase inhibitor in brain disorders.</article-title>
            <source>Postepy Hig Med Dosw (Online)</source>
            <year>2017</year>
            <month>Mar</month>
            <day>02</day>
            <volume>71</volume>
            <issue>0</issue>
            <fpage>137</fpage>
            <page-range>137-148</page-range>
            <pub-id pub-id-type="pmid">28258674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rolan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hutchinson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>17</issue>
            <fpage>2897</fpage>
            <page-range>2897-904</page-range>
            <pub-id pub-id-type="pmid">19929708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Mihalov</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Carlson</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Mattia</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Regulatory status of caffeine in the United States.</article-title>
            <source>Nutr Rev</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>72 Suppl 1</volume>
            <fpage>23</fpage>
            <page-range>23-33</page-range>
            <pub-id pub-id-type="pmid">25293541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nehlig</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Daval</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Debry</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects.</article-title>
            <source>Brain Res Brain Res Rev</source>
            <year>1992</year>
            <season>May-Aug</season>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>139</fpage>
            <page-range>139-70</page-range>
            <pub-id pub-id-type="pmid">1356551</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Lie</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction.</article-title>
            <source>P T</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>38</volume>
            <issue>7</issue>
            <fpage>407</fpage>
            <page-range>407-19</page-range>
            <pub-id pub-id-type="pmid">24049429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r14">
          <label>14</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Dhaliwal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>PDE5 Inhibitors</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>4</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">31751033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r15">
          <label>15</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Jilani</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Preuss</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Theophylline</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">30085566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwenkgrub</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zaremba</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Joniec-Maciejak</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cudna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mirowska-Guzel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kurkowska-Jastrz&#x00119;bska</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson's disease.</article-title>
            <source>PLoS One</source>
            <year>2017</year>
            <volume>12</volume>
            <issue>7</issue>
            <fpage>e0182019</fpage>
            <pub-id pub-id-type="pmid">28753652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r17">
          <label>17</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Patra</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Corley</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Dimri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brady</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <chapter-title>Biochemistry, cAMP</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">30571052</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r18">
          <label>18</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Pasmanter</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Iheanacho</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hashmi</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <chapter-title>Biochemistry, Cyclic GMP</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>9</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">31194391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bergstrand</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Phosphodiesterase inhibition and theophylline.</article-title>
            <source>Eur J Respir Dis Suppl</source>
            <year>1980</year>
            <volume>109</volume>
            <fpage>37</fpage>
            <page-range>37-44</page-range>
            <pub-id pub-id-type="pmid">6160042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hassan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Dorjay</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Anwar</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Pentoxifylline and its applications in dermatology.</article-title>
            <source>Indian Dermatol Online J</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>510</fpage>
            <page-range>510-6</page-range>
            <pub-id pub-id-type="pmid">25396144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aviado</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects.</article-title>
            <source>Pharmacotherapy</source>
            <year>1984</year>
            <season>Nov-Dec</season>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>297</fpage>
            <page-range>297-307</page-range>
            <pub-id pub-id-type="pmid">6393073</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ribeiro</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Sebasti&#x000e3;o</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Caffeine and adenosine.</article-title>
            <source>J Alzheimers Dis</source>
            <year>2010</year>
            <volume>20 Suppl 1</volume>
            <fpage>S3</fpage>
            <page-range>S3-15</page-range>
            <pub-id pub-id-type="pmid">20164566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Porst</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Giuliano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Glina</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ralph</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Casab&#x000e9;</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Elion-Mboussa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Whitaker</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial.</article-title>
            <source>Eur Urol</source>
            <year>2006</year>
            <month>Aug</month>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>351</fpage>
            <page-range>351-9</page-range>
            <pub-id pub-id-type="pmid">16766116</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kedia</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Uckert</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Assadi-Pour</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kuczyk</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Albrecht</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties.</article-title>
            <source>Ther Adv Urol</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-41</page-range>
            <pub-id pub-id-type="pmid">23372609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r25">
          <label>25</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Preuss</surname>
                <given-names>CV</given-names>
              </name>
            </person-group>
            <chapter-title>Inamrinone</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>3</month>
            <day>24</day>
            <pub-id pub-id-type="pmid">31194440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thakur</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Thakur</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Mohindroo</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Thakur</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Negi</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Hearing loss with phosphodiesterase-5 inhibitors: a prospective and objective analysis with tadalafil.</article-title>
            <source>Laryngoscope</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>123</volume>
            <issue>6</issue>
            <fpage>1527</fpage>
            <page-range>1527-30</page-range>
            <pub-id pub-id-type="pmid">23553123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khan</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dwivedi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Viagra deafness--sensorineural hearing loss and phosphodiesterase-5 inhibitors.</article-title>
            <source>Laryngoscope</source>
            <year>2011</year>
            <month>May</month>
            <volume>121</volume>
            <issue>5</issue>
            <fpage>1049</fpage>
            <page-range>1049-54</page-range>
            <pub-id pub-id-type="pmid">21520123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laties</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sharlip</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction.</article-title>
            <source>J Sex Med</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>12</fpage>
            <page-range>12-27</page-range>
            <pub-id pub-id-type="pmid">16409214</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laties</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zrenner</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Viagra (sildenafil citrate) and ophthalmology.</article-title>
            <source>Prog Retin Eye Res</source>
            <year>2002</year>
            <month>Sep</month>
            <volume>21</volume>
            <issue>5</issue>
            <fpage>485</fpage>
            <page-range>485-506</page-range>
            <pub-id pub-id-type="pmid">12207947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kloner</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.</article-title>
            <source>Am J Cardiol</source>
            <year>2005</year>
            <month>Dec</month>
            <day>26</day>
            <volume>96</volume>
            <issue>12B</issue>
            <fpage>42M</fpage>
            <page-range>42M-46M</page-range>
            <pub-id pub-id-type="pmid">16387566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The Association Between Phosphodiesterase Type 5 Inhibitor Use and Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis.</article-title>
            <source>Sex Med</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>185</fpage>
            <page-range>185-192</page-range>
            <pub-id pub-id-type="pmid">29884471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ross</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Allen-Webb</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Pappas</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>McGough</surname>
                <given-names>EC</given-names>
              </name>
            </person-group>
            <article-title>Amrinone-associated thrombocytopenia: pharmacokinetic analysis.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>1993</year>
            <month>Jun</month>
            <volume>53</volume>
            <issue>6</issue>
            <fpage>661</fpage>
            <page-range>661-7</page-range>
            <pub-id pub-id-type="pmid">8513658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r33">
          <label>33</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Journey</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Bentley</surname>
                <given-names>TP</given-names>
              </name>
            </person-group>
            <chapter-title>Theophylline Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">30422557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cappelletti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Piacentino</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fineschi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Frati</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cipolloni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Aromatario</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Caffeine-Related Deaths: Manner of Deaths and Categories at Risk.</article-title>
            <source>Nutrients</source>
            <year>2018</year>
            <month>May</month>
            <day>14</day>
            <volume>10</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">29757951</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Treatment of caffeine toxicity with metoprolol.</article-title>
            <source>Am J Emerg Med</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>562.e5</fpage>
            <page-range>562.e5-562.e10</page-range>
            <pub-id pub-id-type="pmid">30514596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27139.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Price</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Fligner</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Treatment of caffeine toxicity with esmolol.</article-title>
            <source>Ann Emerg Med</source>
            <year>1990</year>
            <month>Jan</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <page-range>44-6</page-range>
            <pub-id pub-id-type="pmid">1688693</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
